RenovoRx Inc (RNXT) - Total Assets
Based on the latest financial reports, RenovoRx Inc (RNXT) holds total assets worth $8.10 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See RNXT equity to assets ratio to measure how much of total assets are equity-financed.
RenovoRx Inc - Total Assets Trend (2019–2025)
This chart illustrates how RenovoRx Inc's total assets have evolved over time, based on quarterly financial data. Check tangible equity quality of RenovoRx Inc to evaluate the tangible quality of the company's equity base.
RenovoRx Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
RenovoRx Inc's total assets of $8.10 Million consist of 97.5% current assets and 2.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.8% |
| Accounts Receivable | $139.00K | 1.7% |
| Inventory | $189.00K | 2.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how RenovoRx Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RNXT market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RenovoRx Inc's current assets represent 97.5% of total assets in 2025, a decrease from 99.8% in 2019.
- Cash Position: Cash and equivalents constituted 86.8% of total assets in 2025, down from 92.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 2.3% of total assets.
RenovoRx Inc Competitors by Total Assets
Key competitors of RenovoRx Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
RenovoRx Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.02 | 4.10 | 0.21 |
| Quick Ratio | 3.93 | 4.10 | 0.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.93 Million | $5.92 Million | $-3.64 Million |
RenovoRx Inc - Advanced Valuation Insights
This section examines the relationship between RenovoRx Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.22 |
| Latest Market Cap to Assets Ratio | 4.73 |
| Asset Growth Rate (YoY) | -0.3% |
| Total Assets | $8.10 Million |
| Market Capitalization | $38.29 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values RenovoRx Inc's assets at a significant premium (4.73x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: RenovoRx Inc's assets decreased by 0.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for RenovoRx Inc (2019–2025)
The table below shows the annual total assets of RenovoRx Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $8.10 Million | -0.28% |
| 2024-12-31 | $8.12 Million | +453.75% |
| 2023-12-31 | $1.47 Million | -79.82% |
| 2022-12-31 | $7.26 Million | -55.39% |
| 2021-12-31 | $16.29 Million | +750.94% |
| 2020-12-31 | $1.91 Million | -15.68% |
| 2019-12-31 | $2.27 Million | -- |
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded i… Read more